Patents Issued in August 1, 2017
-
Patent number: 9717768Abstract: The present invention relates to a bacteriophage having a specific bactericidal activity against Salmonella, a composition for the prevention or treatment of infectious diseseases comprising the bacteriophage as an active ingredient, an antibiotic comprising the bacteriophage as an active ingredient, an animal feed or drinking water comprising the bacteriophage as an active ingredient, and a sanitizer or cleaner comprising the bacteriophage as an active ingredient. The bacteriophage of the present nvention has a specific bactericidal activity against Salmonella choleraesuis, Salmonella typhimurium, Salmonella derby, Salmonella infantis, or Salmonella newport with no influences on beneficial bacteria, as well as excellent acid- and heat-resistance and desiccation tolerance.Type: GrantFiled: September 20, 2012Date of Patent: August 1, 2017Assignee: CJ CHEILJEDANG CORPORATIONInventors: Si Yong Yang, Jae Won Kim, Young Wook Cho, Young Sa Kim, Eun Mi Shin
-
Patent number: 9717769Abstract: The present invention relates to a method for protecting a kidney, which comprises administering an extracellular polysaccharide produced by Ceriporia lacerata; a mycelial culture medium of Ceriporia lacerata containing the extracellular polysaccharide; dried powders of the mycelial culture medium; or an extract of the mycelial culture medium, in an effective amount, to a subject in need of protecting a kidney. The method is effective in protecting a kidney from renal toxicity caused by an anti-cancer agent.Type: GrantFiled: November 25, 2016Date of Patent: August 1, 2017Assignee: FUGENBIOPHARMA CO., LTD.Inventors: Yoon Soo Kim, Hye Dong Yoo, Eun Ji Shin
-
Patent number: 9717770Abstract: The present disclosure provides mixtures of prenylated flavonoids, stilbenes, or both with flavans or curcuminoids or both capable of useful for promoting, managing or improving bone health, cartilage health or both, or for preventing or treating a bone disorder, cartilage disorder or both. Such a mixture of prenylated flavonoids, stilbenes, or both with flavans or curcuminoids or both can optionally be used in combination with other bone and cartilage management agents, such as calcium, magnesium, zinc, boron, vitamin D, vitamin K, glucosamine and/or chondroitin compounds, non-steroidal anti-inflammatory agents/analgesics, COX/LOX inhibiting agents, neuropathic pain relief agents, or the like.Type: GrantFiled: June 16, 2015Date of Patent: August 1, 2017Assignee: Unigen, Inc.Inventors: Lidia Alfaro Brownell, Min Chu, Mei-Feng Hong, Eu-Jin Hyun, Qi Jia, Ping Jiao, Hyun-Jin Kim, Mi-Ran Kim, Tae-Woo Kim, Young-Chul Lee, Jeong-Bum Nam, Mesfin Yimam
-
Patent number: 9717771Abstract: This invention relates to novel extracts from sugar cane and sugar beet molasses and the characterization of those extracts. The extracts are enriched in hydrophobic compounds including polyphenols, in levels 5 to 10 fold higher than found in molasses itself. Methods for extracting the extract are also described, together with new uses for the extracts as food ingredients, food modifiers and therapeutic substances.Type: GrantFiled: December 15, 2016Date of Patent: August 1, 2017Assignee: THE PRODUCT MAKERS (AUSTRALIA) PTY LTDInventors: Leodevico Luna Ilag, Jason Smythe, Timothy Peter Ellis, Richard Stuart Weisinger
-
Patent number: 9717772Abstract: Methods for the prevention and treatment of ocular disorders, in particular glaucoma, through blocking the toxic effects of ?-amyloid (A?) derivatives, pharmaceutical compositions for effecting such prevention and interval treatment thereof.Type: GrantFiled: June 20, 2013Date of Patent: August 1, 2017Assignee: Ramot at Tel-Aviv University Ltd.Inventors: Hermann Russ, Wojciech Danysz, Christopher Graham Raphael Parsons
-
Patent number: 9717773Abstract: New Lactococcus lactis strains, NRRL B-50571 and NRRL B-50572, and a bacterial preparation containing the same, have the ability to produce bioactive peptides that reduce blood pressure, lower LDL-cholesterol (bad cholesterol) and present antioxidant properties for better cardiovascular health. These biologically active peptides may be produced within the food for the production of a food product, such as a functional food, or they may be produced from protein sources and subsequently added to a food as part of the formulation or as part of a food supplement or a pharmaceutical preparation.Type: GrantFiled: February 17, 2016Date of Patent: August 1, 2017Assignees: CENTRO DE INVESTIGACION EN ALIMENTACION Y DESARROLLO, A.C. (CIAD), VALLEJO GALLAND, BELINDA, CORDOVA, AARON FERNANDO GONZALESInventors: Belinda Vallejo Galland, Aarón Fernando González Córdova, Jóse Carlos Rodriguez Figueroa
-
Patent number: 9717774Abstract: The present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated cytotoxic T cell (CTL) peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses. The present invention relates to 95 novel peptide sequences and their variants derived from HLA class I molecules of human tumor cells that can be used in vaccine compositions for eliciting anti-tumor immune responses.Type: GrantFiled: February 6, 2015Date of Patent: August 1, 2017Assignee: IMMATICS BIOTECHNOLOGIES GMBHInventors: Jens Fritsche, Toni Weinschenk, Steffen Walter, Peter Lewandrowski, Harpreet Singh
-
Patent number: 9717775Abstract: The present invention relates to the use of compounds that block the ?9?10 subtype of the nicotinic acetylcholine receptor (nAChR) for treating pain, such as neuropathic pain and inflammatory pain, and inflammatory disorders, such as arthritis. The present invention also relates to screening compounds to identify analgesic agents that block the ?9?10 subtype of the nAChR.Type: GrantFiled: July 17, 2007Date of Patent: August 1, 2017Assignee: University of Utah Research FoundationInventors: J. Michael McIntosh, Baldomero M. Olivera, Michael A. Ellison, Michelle Vincler
-
Patent number: 9717776Abstract: The invention relates to vesicles comprising Epidermal Growth Factor (EGF), a cationic surfactant and cholesterol or derivatives thereof. The invention also discloses a procedure for their preparation, based on compressed fluid technology (CFs). The vesicles of the invention are useful in the manufacture of drugs and cosmetics and in tissue engineering.Type: GrantFiled: August 2, 2013Date of Patent: August 1, 2017Assignees: CENTRO DE INGENIERÍA GENÉTICA Y BIOTECNOLOGÍA, CONSEJO SUPERIOR DE INVESTIGACIONES CENTÍFICASInventors: Héctor Jesús Santana Milián, Leonor Ventosa Rull, Eduardo Martínez Díaz, Jorge Amador Berlanga Acosta, Ingrid Cabrera Puig, Jaume Veciana Miró
-
Patent number: 9717777Abstract: A method of treating a medical condition in which suppression of effector T cells is beneficial in a subject in need thereof is disclosed. The method comprising administering to the subject a therapeutically effective amount of a CCL1 polypeptide, thereby treating the medical condition in the subject.Type: GrantFiled: May 25, 2016Date of Patent: August 1, 2017Assignee: RAPPAPORT FAMILY INSTITUTE FOR RESEARCH IN THE MEDICAL SCIENCESInventors: Nathan Karin, Yiftah Barsheshet, Gizi Wildbaum
-
Patent number: 9717778Abstract: The present disclosure relates to a method for treatment or prevention of diseases have an increased level of insulin-like growth factor I (IGF-I). The method comprises administration of a growth hormone (GH) variant having antagonistic activity in combination with an oligonucleotide targeted to growth hormone receptor (GHR) to a subject in need.Type: GrantFiled: February 4, 2013Date of Patent: August 1, 2017Assignee: Antisense Therapeutics Ltd.Inventor: George Tachas
-
Patent number: 9717779Abstract: Implantable matrices and methods are provided. The matrices are configured to fit at or near a target tissue site, the matrices comprise biodegradable materials and ligands bound to the matrices and are configured to bind receptors and allow influx of cells into the implantable matrices, wherein the ratio of ligands to receptors is from about 1.5 to about 0.5.Type: GrantFiled: January 31, 2011Date of Patent: August 1, 2017Assignee: Warsaw Orthopedic, Inc.Inventor: Vanja Margareta King
-
Patent number: 9717780Abstract: The present invention is based upon the identification of a number of antigens derived from species of the genus Teladorsagia, which can be used to raise immune responses in animals—particularly those animals susceptible or predisposed to infection by (or with) one or more Teladorsagia species. The antigens may be exploited to provide compositions and vaccines for raising protective immune responses in animals—the protective immune responses serving to reduce, prevent, treat or eliminate Teladorsagia infections/infestations.Type: GrantFiled: February 4, 2013Date of Patent: August 1, 2017Assignee: Moredun Research InstituteInventors: Jacqueline Matthews, Alasdair Justice Nisbet, David Knox
-
Patent number: 9717781Abstract: Provided herein are novel p62 compositions for the prophylaxis and treatment of cancer and related methods. The invention also provides modified p62 compositions that increase the anti-cancer activity of p62.Type: GrantFiled: August 8, 2012Date of Patent: August 1, 2017Inventors: Alexander Shneider, Franco Venanzi, Michael Sherman, Victor Shifrin
-
Patent number: 9717782Abstract: Methods for producing an immune response to Mycobacterium tuberculosis (Mtb) are disclosed herein. In several examples, the immune response is a protective immune response. In additional embodiments, methods are disclosed for inhibiting an infection with Mtb, preventing an infection with Mtb, or treating an infection with Mtb. Pharmaceutical compositions for the inhibition, prevention and/or treatment of tuberculosis are also disclosed.Type: GrantFiled: October 17, 2016Date of Patent: August 1, 2017Assignees: Oregon Health & Science University, The United States of America as represented by the Department of Veterans AffairsInventors: David M. Lewinsohn, Deborah A. Lewinsohn
-
Patent number: 9717783Abstract: The invention provides immunotherapeutic and prophylactic bacteriophage viral-like particle (VLPs) which are useful in the treatment and prevention of human papillomavirus (HPV) infections and related disorders, including cervical cancer and persistent infections associated with HPV. Related compositions (e.g. vaccines), nucleic acid constructs, and therapeutic methods are also provided. VLPs and related compositions of the invention induce high titer antibody responses against HPV L2 and protect against HPV challenge in vivo. VLPs, VLP-containing compositions, and therapeutic methods of the invention induce an immunogenic response against HPV infection, confer immunity against HPV infection, protect against HPV infection, and reduce the likelihood of infection by HPV infection.Type: GrantFiled: July 19, 2013Date of Patent: August 1, 2017Assignee: STC.UNMInventors: Bryce Chackerian, David S. Peabody, Ebenezer Tumban
-
Patent number: 9717784Abstract: The genome sequences and the nucleotide sequences coding for the PWD circovirus polypeptides, such as the circovirus structural and non-structural polypeptides, vectors including the sequences, and cells and animals transformed by the vectors are provided. Methods for detecting the nucleic acids or polypeptides, and kits for diagnosing infection by a PWD circovirus, also are provided. Method for selecting compounds capable of modulating the viral infection are further provided. Pharmaceutical, including vaccine, compositions for preventing and/or treating viral infections caused by PWD circovirus and the use of vectors for preventing and/or treating diseases also are provided.Type: GrantFiled: November 14, 2014Date of Patent: August 1, 2017Assignee: Zoetis Services LLCInventors: André Jestin, Emmanuel Albina, Pierre Le Cann, Philippe Blanchard, Evelyne Hutet, Claire Arnauld, Catherine Truong, Dominique Mahe, Roland Cariolet, François Madec
-
Patent number: 9717785Abstract: The present invention relates to the preparation of the recombinant antigen of the viral capsid of Porcine circovirus 2 (PCV-2) and modifications thereof, upon expression in a prokaryotic system, purification in the monomer form, recovery of virus-like particles (VLPs) and their use in vaccine formulations, diagnostic kits and a system for quantifying in vaccine lots of the PCV-2 antigen by means of a capture ELISA assay. The antigens and vaccine formulations can be used in animal's immunization in programs for combatting PCV-2-associated diseases in conventional swine breeding systems, and represent alternatives to the commercially available vaccines. The ELISA kit can be used for testing the quality of commercial and/or experimental vaccines against PCV-2.Type: GrantFiled: January 23, 2014Date of Patent: August 1, 2017Assignees: FUNDAÇÃO DE AMPARO À PESQUISA DO ESTADO DE MG-FAPEMIG, UNIVERSIDADE FEDERAL DE VIÇOSAInventors: Márcia Rogéria De Almeida, Abelardo Silva Junior, Juliana Lopes Rangel Fietto, Gustavo Costa Bressan, Rafael Locatelli Salgado, Thiago Souza Onofre, Mariana Costa Fausto, Pedro Marcus Pereira Vidigal, Sthefany Patareli Kalks, Josicelli Souza Crispim, Roberta Amaziles Silva Leite, Jackson de Andrade Teixeira, Natália Fialho Gonzaga, Tiago Jaquel Zilch, Luiz Fernando Lino De Souza, Amanda Martins De Cruz Souza, Antônio De Morais Monteiro
-
Patent number: 9717786Abstract: The present invention is generally related to modified or mutated respiratory syncytial virus fusion (F) proteins and methods for making and using them, including immunogenic compositions such as vaccines for the treatment and/or prevention of RSV infection.Type: GrantFiled: June 4, 2015Date of Patent: August 1, 2017Assignee: Novavax, Inc.Inventors: Peter M. Pushko, Yingyun Wu, Michael J Massare, Ye Liu, Gale Smith, Bin Zhou
-
Patent number: 9717787Abstract: Provided herein are recombinant modified vaccinia virus Ankara (MVA) strains as improved vaccines against infection with Respiratory Syncytial Virus (RSV virus) and to related products, methods and uses. Specifically, provided herein are genetically engineered recombinant MVA vectors comprising at least one nucleotide sequence encoding an antigenic determinant of an RSV membrane glycoprotein and at least one nucleotide sequence encoding an antigenic determinant of an RSV nucleocapsid protein. Also provided herein are products, methods and uses thereof, e.g., suitable to affect an immune response in a subject, or suitable to diagnose an RSV infection, as well as to determine whether a subject is at risk of recurrent RSV infection.Type: GrantFiled: October 14, 2016Date of Patent: August 1, 2017Assignee: BAVARIAN NORDIC A/SInventors: Cédric Cheminay, Robin Steigerwald, Paul Chaplin
-
Patent number: 9717788Abstract: The present invention relates to, inter alia, a method of raising an immune response against a pathogen which comprises administering (i) one or more first immunogenic polypeptides derived from said pathogen; (ii) one or more adenoviral vectors comprising one or more heterologous polynucleotides encoding one or more second immunogenic polypeptides derived from said pathogen; and (iii) an adjuvant; wherein the one or more first immunogenic polypeptides, the one or more adenoviral vectors and the adjuvant are administered concomitantly. The invention also relates to vaccines, pharmaceutical compositions, kits and uses employing said polypeptides, adenoviral vectors and adjuvants.Type: GrantFiled: January 18, 2013Date of Patent: August 1, 2017Assignee: GLAXOSMITHKLINE BIOLOGICALS SAInventor: Gerald Hermann Voss
-
Patent number: 9717789Abstract: The present invention relates, in general, to human immunodeficiency virus (HIV), and, in particular, to a method of inducing neutralizing antibodies to HIV and to compounds and compositions suitable for use in such a method.Type: GrantFiled: June 28, 2016Date of Patent: August 1, 2017Assignee: DUKE UNIVERSITYInventors: Barton F. Haynes, S. Munir Alam, Hua-Xin Liao
-
Patent number: 9717790Abstract: The invention relates to sphingoglycolipid analogues which are useful in treating or preventing diseases and conditions such as those relating to infection, atopic disorders, autoimmune diseases or cancer.Type: GrantFiled: June 10, 2014Date of Patent: August 1, 2017Assignee: Victoria Link LimitedInventors: Regan James Anderson, Benjamin Jason Compton, Colin Malcolm Hayman, Ian Francis Hermans, Karen Anne Johnston, David Samuel Larsen, Gavin Frank Painter
-
Patent number: 9717791Abstract: The disclosure relates to novel regimens for treating psoriasis, which employ a therapeutically effective amount of an IL-17 antagonist, e.g., an IL-17 binding molecule, e.g., an IL-17 antibody, such as the secukinumab antibody, or an IL-17 receptor binding molecule, e.g., an IL-17 receptor antibody.Type: GrantFiled: October 7, 2011Date of Patent: August 1, 2017Assignee: Novartis AGInventors: Achim Guettner, Matthias Machacek, Charis Papavassilis, Oliver Sander
-
Patent number: 9717792Abstract: Combination therapy for cancer makes use of HSP27 inhibitors and EGFR tyrosine kinase inhibitors or etiolates.Type: GrantFiled: February 1, 2013Date of Patent: August 1, 2017Assignee: The University of British ColumbiaInventors: Martin E. Gleave, Amina Zoubeidi, Masafumi Kumano
-
Method of improving patient survivability and quality of life by administering an anti-IL-6 antibody
Patent number: 9717793Abstract: The present invention is directed to therapeutic methods using IL-6 antagonists such as antibodies and fragments thereof having binding specificity for IL-6 to improve survivability or quality of life of a patient in need thereof. In preferred embodiments, the anti-IL-6 antibodies will be humanized and/or will be aglycosylated. Also, in preferred embodiments these patients will comprise those exhibiting (or at risk of developing) an elevated serum C-reactive protein level or a reduced serum albumin level prior to treatment. In another preferred embodiment, the patient's Glasgow Prognostic Score will be increased and survivability will preferably be improved.Type: GrantFiled: January 23, 2015Date of Patent: August 1, 2017Assignee: ALDERBIO HOLDINGS LLCInventor: Jeffrey T. L. Smith -
Patent number: 9717794Abstract: The present invention relates to compositions and methods for characterizing, diagnosing and treating cancer. In particular, the present invention identifies LGR5 as a protein over-expressed in solid tumor stem cell. The present invention further identifies an interaction between RSPO1 and LGR5 as an alternative pathway for the activation of beta-catenin signaling. In certain embodiments, the present invention provides biomolecules that disrupt functional signaling via a LGR protein, including, in certain embodiments, molecules that inhibit the interaction between one or more RSPO proteins and one or more LGR proteins, such as LGR5. In certain embodiments, the present invention provides methods of treating cancer comprising disrupting functional LGR signaling and inhibiting growth of a solid tumor comprising solid tumor stem cells.Type: GrantFiled: April 22, 2015Date of Patent: August 1, 2017Assignee: ONCOMED PHARMACEUTICALS, INC.Inventors: Austin L. Gurney, Aaron K. Sato
-
Patent number: 9717795Abstract: Disclosed are a HPPH lyophilized powder injection for injection and the preparation method thereof. The HPPH lyophilized powder injection contains HPPH, auxiliary solvents, solubilizing agents, excipients, and pH adjusting agents. The HPPH lyophilized powder injection is loose and has good resolubility, low moisture, and good stability.Type: GrantFiled: January 21, 2014Date of Patent: August 1, 2017Assignee: ZHEJIANG HISUN PHARMACEUTICAL CO., LTD.Inventors: Chunrong Feng, Huanwei Zhang, Jianqiao Wang
-
Patent number: 9717796Abstract: The presently disclosed subject matter relates to pharmaceutical compositions comprising dexmedetomidine or a pharmaceutically acceptable salt thereof wherein the composition is formulated as a liquid for parenteral administration to a subject, and wherein the composition is disposed in a flexible plastic container as a ready to use premixed solution.Type: GrantFiled: April 20, 2016Date of Patent: August 1, 2017Assignee: SLYPHARMA, LLCInventor: Joseph M. Pizza
-
Patent number: 9717797Abstract: Nanoparticles comprise a drug, a first block polymer and a second block polymer. The first block polymer has a poly(ethylene oxide) (PEO) block and a polycarbonate block bearing a side chain aromatic nitrogen-containing heterocycle (N-heterocycle). The N-heterocycle can be in the form of a base, a hydrosalt of the base, a sulfobetaine adduct of the base, or a combination thereof. The second block polymer has a PEO block and a polycarbonate block bearing a side chain catechol group, which can be present as a catechol, oxidized form of a catechol, and/or a polymerized form of a catechol. The nanoparticles can be dispersed in water and are capable of controlled release of the drug.Type: GrantFiled: December 5, 2013Date of Patent: August 1, 2017Assignees: International Business Machines Corporation, Agency For Science, Technology And Research, Universidad del París Vasco/Euskal Herriko UnibertsitateaInventors: Julian M. W. Chan, Amanda C. Engler, James L. Hedrick, Xiyu Ke, Victor W. L. Ng, Haritz Sardon, Jeremy P. K. Tan, Yi Yan Yang
-
Patent number: 9717798Abstract: A composition is disclosed. The composition comprises at least one polymeric colorant having a polymer component with a colorant component covalently bound thereto, a medicament, and a liquid vehicle. The at least one colorant component does not react directly or indirectly with the medicament. Methods of using the polymeric colorants, including a method for the preparation of skin as a site for a surgical procedure and a method of treating a medical condition, are also provided.Type: GrantFiled: November 16, 2012Date of Patent: August 1, 2017Assignee: 3M Innovative Properties CompanyInventors: Louis C. Haddad, Douglas A. Hanggi, David B. Olson, Matthew T. Scholz, Dong-Wei Zhu
-
Patent number: 9717799Abstract: The present invention provides implants comprising a therapeutic drug and a polymer containing polylactic acid (PLA) and optionally polyglycolic acid (PGA). The present invention also provides methods of maintaining a therapeutic level of a drug in a subject, releasing a therapeutic drug at a substantially linear rate, and treating schizophrenia and other diseases and disorders, utilizing implants of the present invention.Type: GrantFiled: November 13, 2014Date of Patent: August 1, 2017Assignee: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIAInventors: Steven Siegel, Karen Winey
-
Patent number: 9717800Abstract: The present invention relates to a pharmaceutical composition comprising fingolimod and a weak acid cation exchange resin in the form of an ion-exchange complex and pharmaceutically acceptable 5 excipients.Type: GrantFiled: September 1, 2015Date of Patent: August 1, 2017Assignee: SUN PHARMACEUTICAL INDUSTRIES LTD.Inventors: Sunil Jaiswal, Krishna Sharma, Nitin Bhalachandra Dharmadhikari, Shirish Kulkarni
-
Patent number: 9717801Abstract: The present invention relates to glycogen-based cationic polymers, to complexes of the said cationic polymers with anionic compounds, to pharmaceutical compositions comprising the said complexes, and to the use of the said complexes for delivering or transfecting the said anionic compounds to a specific pharmacological target, such as, for instance an organ, a tissue or a cell.Type: GrantFiled: February 21, 2013Date of Patent: August 1, 2017Assignee: AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.p.A.Inventors: Vincenzo Russo, Elisa Liberati, Nicola Cazzolla
-
Patent number: 9717802Abstract: Improved N-terminal capping modules for designed Ankyrin repeat proteins (DARPins) conferring improved thermal stability to the DARPins are described, as well as nucleic acids encoding such proteins, pharmaceutical compositions comprising such proteins and the use of such proteins in the treatment of diseases.Type: GrantFiled: November 20, 2015Date of Patent: August 1, 2017Assignee: Molecular Partners AGInventor: Hans Kaspar Binz
-
Patent number: 9717803Abstract: The present application relates to methods for the functionalization of immunoglobulins, in particular with drugs. Also disclosed herein are linking reagents, functionalized antibodies, pharmaceutical compositions, and method of treating disease and/or conditions.Type: GrantFiled: December 21, 2012Date of Patent: August 1, 2017Assignees: INNATE PHARMA, PAUL SCHERRER INSTITUTInventors: Delphine Bregeon, Patrick Dennler, Christian Belmant, Eliane Fischer, Laurent Gauthier, Francois Romagné, Roger Schibli
-
Patent number: 9717804Abstract: Methods for producing new neurons in the brain in vivo are provided according to aspects of the present invention which include introducing NeuroD1 into a glial cell, particularly into a reactive astrocyte or NG2 cell, thereby “converting” the reactive glial cell to a neuron. Methods of producing a neuronal phenotype in a glial cell are provided according to aspects of the present invention which include expressing exogenous NeuroD1 in the glial cell, wherein expressing exogenous NeuroD1 includes delivering an expression vector, such as a viral expression vector, including a nucleic acid encoding the exogenous NeuroD1 to the glial cell.Type: GrantFiled: July 19, 2013Date of Patent: August 1, 2017Assignee: The Penn State Research FoundationInventors: Gong Chen, Lei Zhang, Zheng Wu, Yuchen Chen, Fan Wang, Ziyuan Guo
-
Patent number: 9717805Abstract: The present invention relates to an image enhancing composition for the enhancement of contrast in a body cavity, wherein the viscosity of the composition is between 2000 and 4000 mPa·sec. It also relates to a method for enhancing contrast of an image of a body cavity, which method comprises introducing one single small amounts of an image enhancing composition into the body cavity. In another aspect, the present invention provides a high contrast image of a body cavity obtained by the method of the invention, in particular a 3-dimensional high contrast image.Type: GrantFiled: March 19, 2015Date of Patent: August 1, 2017Assignee: GynaecologIQ B.V.Inventors: Mark Hans Emanuel, Niek Exalto
-
Patent number: 9717806Abstract: A method of detecting an accessory cancer lesion, comprising an administration step wherein indocyanine green is administered to a living body, an irradiation step wherein a target organ suspected of having cancer is surgically exposed and irradiated with excitation light of indocyanine green, an imaging step wherein a near-infrared fluorescence intensity distribution image from the excited indocyanine green in the target organ is obtained, and an identification step wherein an area having the near-infrared fluorescence in the intensity distribution image, excluding the area detected in preoperative examination or intraoperative macroscopic observation, is identified as an accessory cancer lesion.Type: GrantFiled: December 19, 2014Date of Patent: August 1, 2017Assignees: OSAKA PREFECTURAL HOSPITAL ORGANIZATION, HAMAMATSU PHOTONICS K.K.Inventors: Osamu Ishikawa, Terumasa Yamada, Kunihito Gotoh, Mitsuharu Miwa, Takahiro Shikayama
-
Patent number: 9717807Abstract: The present invention relates to a CT contrast agent for detecting a thrombus, comprising fibrin-targeted peptide sequence-conjugated glycol chitosan-gold nanoparticles. The CT contrast agent for detecting a thrombus according to an embodiment of the present invention may allow rapid and repeated acquisition of CT image information related to the size and location of a thrombus in cardio-cerebral vascular thrombosis, and also enables the imaging monitoring of cerebral thrombus.Type: GrantFiled: May 13, 2013Date of Patent: August 1, 2017Assignees: Dongguk University Industry-Academic Cooperation Foundation, SNU R & DB Foundation, Korea Institute of Science and TechnologyInventors: Dong Eog Kim, Jeong Yeon Kim, In Cheol Sun, Sung Kyung Park, Cheol Hee Ahn, Kwang Meyung Kim
-
Patent number: 9717808Abstract: The invention relates to a kit for preparation of target radiopharmaceuticals, a method of using the kit to prepare target radiopharmaceuticals and use of the target radiopharmaceuticals. The target radiopharmaceuticals comprise a radio-nuclear loading on liposome and inhibit the tumor growth and metastatic progression of head and neck cancer, lung cancer and brain cancer. The radiopharmaceuticals may be used for treating the mentioned cancers.Type: GrantFiled: November 3, 2014Date of Patent: August 1, 2017Assignee: INSTITUTE OF NUCLEAR ENERGY RESEARCH ATOMIC ENERGY COUNCIL, EXECUTIVE YUANInventors: Shu-Pei Chiu, Bo-Sian Lin, Liang-Ting Lin, Yi-Jang Lee, Te-Wei Lee, Feng-Yun Huang, Jem-Mau Lo
-
Patent number: 9717809Abstract: A system and apparatus for sanitizing devices with complex shapes. The system is comprised essentially of a mechanism for emitting sanitizing electromagnetic radiation within an enclosed compartment. The apparatus may be light-tight such that the radiation is contained within the apparatus. It may be configured to emit a plurality of sanitizing wavelengths. The apparatus may also be sound-tight, limiting or preventing the transmission of acoustic sounds made by the devices being sanitized. The apparatus may include a series of reflective and refractive apparatuses to alter the reflection path of the emitted electromagnetic radiation, allowing the apparatus to be used for devices with complex shapes. The enclosure may include support devices, such as dividers and support plates, that may be transparent to the electromagnetic radiation. The apparatus may include a locking mechanism. The system may include a control module including a user interface.Type: GrantFiled: December 15, 2016Date of Patent: August 1, 2017Inventors: Carrie Martz, Brooke O'Connor
-
Patent number: 9717810Abstract: A system for treating an enclosed area may include a plurality of fogging devices each including a housing, a fluid reservoir, a compressor coupled to the fluid reservoir, an atomizing nozzle in fluid communication with the fluid reservoir, a first wireless transceiver, and a first processor coupled to the compressor and the wireless transceiver. A wireless communications device may include a second wireless transceiver and a second processor to identify the fogging devices within the enclosed area based upon the first and second wireless transceivers, determine respective fogging times for the fogging devices based upon a size of the enclosed area and a number of the foggers identified within the enclosed area, and initiate a treatment cycle during which, on a coordinated schedule, the first processor of each fogging device causes its associated compressor to dispense fluid into the enclosed area via the atomizing nozzle for the respective fogging time.Type: GrantFiled: February 15, 2016Date of Patent: August 1, 2017Inventor: Steven T. Grinstead
-
Patent number: 9717811Abstract: A multi-panel sterilization assembly that includes a barrier panel formed of permeable material having barrier properties, side tabs that include grip portions for folding or unfolding the barrier panel; and a fold protection panel. The barrier panel has a first end and a second end opposite the first end, a first edge and a third edge, each such edge being generally perpendicular to the first end, and a midpoint to generally delineate the barrier panel into a content receiving region extending from approximately the first end to the midpoint and a content covering region extending from the midpoint to approximately the second end. The side tabs are located between the first end and the midpoint of the barrier panel and at or near the first edge and the third edge. The fold protection panel is in juxtaposed communication with the barrier panel such that after folding the content covering region and the first and third edges over the content receiving region, the fold protection panel covers them.Type: GrantFiled: September 27, 2012Date of Patent: August 1, 2017Assignee: Avent, Inc.Inventors: Melissa R. Gaynor, Eric T. Bricker, Jeffrey J. Farmer, Mark T. Pamperin, Corinna Schwarz, Catherine J. Turnbow
-
Patent number: 9717812Abstract: A biological sterilization indicator, system, and methods of determining the effectiveness of a sterilization process. The biological sterilization indicator can include a locus of spores, a reservoir containing a liquid, and a sterilant path positioned to provide fluid communication between ambience and the locus of spores. The reservoir can have a closed state in which the reservoir is not in fluid communication with the locus of spores and an open state in which the reservoir is in fluid communication with the locus of spores. The biological sterilization indicator system can include the biological sterilization indicator and a detection device adapted to be coupled to the biological sterilization indicator. In some embodiments, the method can include assaying the spores for a detectable change in a characteristic, and detecting substantially all of the detectable change.Type: GrantFiled: February 18, 2015Date of Patent: August 1, 2017Assignee: 3M INNOVATIVE PROPERTIES CO.Inventors: Sailaja Chandrapati, Jeffrey C. Pederson, Heather M. Webb, Jeffrey D. Smith, Kurt J. Halverson, Bryan S. Behun, Peter D. Ludowise
-
Patent number: 9717813Abstract: An electrical heating evaporator for evaporating active substances such as perfumes and/or insecticides, in which the evaporation rate regulator includes an electrical heater resistor for which the power supplied is regulated through a potentiometer constructed on a printed circuit board. The evaporation rate can be adjusted for a wide variety of types of chemical substances, without the need of substantially modifying the design of the device.Type: GrantFiled: June 11, 2012Date of Patent: August 1, 2017Assignee: ZOBELE HOLDING SPAInventors: Stefano Deflorian, Juan Antonio Gomez Gracia, Cedric Morhain
-
Patent number: 9717814Abstract: A volatile material dispensing system includes a frame having a front face and a rear face. A first magnetic element is disposed on the frame. A reservoir containing a volatile material is provided. A second magnetic element is disposed on the reservoir.Type: GrantFiled: October 1, 2010Date of Patent: August 1, 2017Assignee: S. C. Johnson & Son, Inc.Inventor: Scott D. Walter
-
Patent number: 9717815Abstract: Automated air freshener dispensers and cartridges therefor are provided herein. Air freshener dispensers include a housing having a cavity for receiving a cartridge containing an air freshening substance for release, a fan that induces an airflow through the housing and directs the airflow to an area outside of the air freshener dispenser, such that released air freshening substance is entrained in the airflow, a motor for driving the fan, at least one sensor, and a controller that receives a signal from the at least one sensor and directs operation of the fan in response thereto.Type: GrantFiled: July 29, 2015Date of Patent: August 1, 2017Assignee: Georgia-Pacific Consumer Products LPInventors: Eric Paul Peterson, Todd Richard Lappi, Daniel M. D'Amico, John Patrick Laitala, Ryan David Carignan
-
Patent number: 9717816Abstract: A deodorization and sterilization apparatus and method, which increases an amount of generated active species and collects floating bacteria or odor materials in air at one place, such that the active species make contact with the collected floating bacteria or odor materials to achieve high-efficiency sterilization and deodorization. A pair of electrodes is provided, plasma discharge is carried out by applying designated voltage between the pair of electrodes, fluid passage holes are provided at corresponding parts of respective electrodes so as to communicate with each other, and at least one absorption member to absorb floating bacteria or odor materials is disposed at the downstream of a fluid passing through the fluid passage holes.Type: GrantFiled: December 6, 2011Date of Patent: August 1, 2017Assignee: SAMSUNG ELECTRONICS CO., LTD.Inventors: Miyamoto Makoto, Takenoshita Kazutoshi, Kumagai Yuuki, Nakayama Yoko
-
Patent number: 9717817Abstract: Cellulosic pulp structures integrating unreacted quantities of an inorganic peroxide and a destabilizing acid, as binary components of an odor control system, absorbent articles incorporating such structures, and various methods of forming the same, are disclosed herein. The components are adapted to react in the presence of an aqueous fluid to produce hydrogen peroxide, thereby providing an antimicrobial and odor mitigating effect.Type: GrantFiled: December 30, 2013Date of Patent: August 1, 2017Assignee: INTERNATIONAL PAPER COMPANYInventor: Brent A. Petersen